The goals of the VC are to enable, broaden and enhance HIV/AIDS research by providing state-of-the-art BSL-2-3 laboratory facilities and equipment, experienced and dedicated professional staff, education, training, virology-specific research materials and assays and protein expression capabilities, all to support multidisciplinary, investigator-initiated basic and clinical HIV/AIDS research. Each of our specific aims represent significant value-added to HIV/AIDS research and the overall CFAR mission as they (i) enable live HIV research among all UAB investigators, (ii) foster the development of HIV/AIDS research by new investigators, (iii) broaden the research capabilities among CFAR faculty, and (iv) encourage research that is translational and multidisciplinary in nature. The services of VC are integral to the AIDS Center as they provide critical support to numerous multidisciplinary basic and clinical HIV/AIDS research programs.
The specific aims for the VC are as follows: 1. To provide and maintain state-of-the-art BSL 2-3 laboratory facilities that are necessary to conduct """"""""live"""""""" HIV research. 2. To provide safety education and training, and ongoing supervision for all faculty and staff that work in the BSL 2-3 Laboratory. 3. To augment AIDS research capabilities through consultation, assay-specific training, and provision of standardized assays and defined molecular and virologic reagents. 4. To develop specialized genetically engineered tools and assays, including cell lines and viral vectors, to help address new and important investigative challenges in HIV/AIDS research. 5. To continue to offer CFAR investigators the molecular biology services, reagents, and training, that allow a rapid progression from cloning of genes to structure and/or function studies of the gene product. This renewal application reflects important changes that have occurred in the academic HIV/AIDS environment nationally and at UAB since this grant was last competitively renewed. The critical services of two cores that were previously operated independently, the Central Virus Culture Core and the Molecular Biology Core, have been combined into a single core that is now referred to as the Virology Core (VC). This strategy is based on similarities in the nature of virology services offered by the two previous cores and is meant to ensure that we are able to retain and continue to provide critical value-added services, while maximizing proficient utilization of precious CFAR resources.

Public Health Relevance

Studies of HIV immunology, pathogenesis and vaccine research all necessitate access to a state-of-the-art BSL-2-3 laboratory with dedicated equipment and personnel trained in the handling of infectious HIV. The Virology Core thus supports the entire spectrum of basic HIV research and represents an integral component of the AIDS Center. Support of the Virology Core is essential for the continuing success of AIDS investigators at UAB.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027767-21A1
Application #
7685030
Study Section
Special Emphasis Panel (ZAI1-SV-A (J3))
Project Start
2009-06-15
Project End
2014-05-31
Budget Start
2009-06-15
Budget End
2010-05-31
Support Year
21
Fiscal Year
2009
Total Cost
$186,004
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Rice, Whitney S; Logie, Carmen H; Napoles, Tessa M et al. (2018) Perceptions of intersectional stigma among diverse women living with HIV in the United States. Soc Sci Med 208:9-17
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Fredericksen, R J; Gibbons, L; Brown, S et al. (2018) Medication understanding among patients living with multiple chronic conditions: Implications for patient-reported measures of adherence. Res Social Adm Pharm 14:540-544
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Subramaniam, Akila; Van Der Pol, William J; Ptacek, Travis et al. (2018) Midtrimester microbial DNA variations in maternal serum of women who experience spontaneous preterm birth. J Matern Fetal Neonatal Med :1-9
Kay, Emma S; Rice, Whitney S; Crockett, Kaylee B et al. (2018) Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes. J Acquir Immune Defic Syndr 77:257-263
Xu, Wanli; Luo, Zhenwu; Alekseyenko, Alexander V et al. (2018) Distinct systemic microbiome and microbial translocation are associated with plasma level of anti-CD4 autoantibody in HIV infection. Sci Rep 8:12863
Smith, Samuel R; Schaaf, Kaitlyn; Rajabalee, Nusrah et al. (2018) The phosphatase PPM1A controls monocyte-to-macrophage differentiation. Sci Rep 8:902
Wang, Yong; Schafer, Cara C; Hough, Kenneth P et al. (2018) Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. J Immunol 201:278-295
Jones, Robert B; Dorsett, Kaitlyn A; Hjelmeland, Anita B et al. (2018) The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1? signaling. J Biol Chem 293:5659-5667

Showing the most recent 10 out of 955 publications